In T2D, CVOTs investigating the GLP1-RAs liraglutide, semaglutide, albiglutide, and dulaglutide have proven efficacy in reducing cardiovascular events [23,24,26,111]. Here, GLP1R is linked to type 2 diabetes mellitus.